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Abstract
Introduction. Diabetes mellitus (DM) is a serious, chronic metabolic disorder commonly complicated by di-
abetic foot ulcers with delayed healing. Metformin was found to have a wound healing effect through several 
mechanisms. The current study investigated the effect of both bone marrow-derived mesenchymal stem cells 
(BM-MSCs) and metformin, considered alone or combined, on the healing of an experimentally induced cuta-
neous wound injury in streptozotocin-induced diabetic rats.
Material and methods. Forty adult male albino rats were used. Diabetes was induced by single intravenous (IV) 
injection of streptozotocin (STZ). Next, two circular full thickness skin wounds were created on the back of the 
animals, then randomly assigned into 4 groups, ten rats each. BM-MSCs were isolated from albino rats, 8 weeks 
of age and labeled by PKH26 before intradermal injection into rats of Group III and IV. Groups I (diabetic 
positive control), II (metformin-treated, 250 mg/kg/d), III (treated with 2×106 BM-MSCs), and IV (wounded rats 
treated both with metformin and BM-MSCs cells). Healing was assessed 3, 7, 14, and 21 days post wound induc-
tion through frequent measuring of wound diameters. Skin biopsies were obtained at the end of the experiment. 
Results. Gross evaluation of the physical healing of the wounds was done. Skin biopsies from the wound areas 
were processed for hematoxylin and eosin (H&E), Masson’s trichrome staining and immunohistochemical 
staining for CD31. The results showed better wound healing in the combined therapy group (IV) as compared 
to monotherapy groups. 
Conclusions. Although both metformin and BM-MSCs were effective in the healing of experimentally induced 
skin wounds in diabetic rats, the combination of both agents appears to be a better synergistic option for the 
treatment of diabetic wound injuries. (Folia Histochemica et Cytobiologica 2019, Vol. 57, No. 3, 127–138)
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Introduction
Diabetes mellitus (DM) is a serious, chronic endo-
crine disorder affecting more than 380 million people 
worldwide by 2013, and is expected to rise to 592 
million by 2035 [1]. The growing population of dia-
betic patients has increased the risk of development 
of complication such as nephropathy, retinopathy, 
neuropathy, and macroangiopathy which leads to dia-
betic foot ulcers with delayed healing and subsequent 
amputation [2]. Reduced angiogenesis and impaired 
production of cytokines by local inflammatory cells 
are crucial factors for delayed healing [3].
The clinical need to develop recent strategies 
of treatment to improve the healing of diabetic ul-
128 Lamiaa M. Shawky et al.
©Polish Society for Histochemistry and Cytochemistry
Folia Histochem Cytobiol. 2019
10.5603/FHC.a2019.0014
www.fhc.viamedica.pl
cerative wounds becomes mandatory. Metformin, 
a biguanide, is one of the most commonly prescribed 
oral anti-hyperglycemic agents for treating type 2 
diabetes mellitus [4]. It exerts its therapeutic effects 
through multiple mechanisms of actions, including 
inhibition of glucose production in the liver. In 
addition, metformin is an insulin enhancer and can 
increase insulin sensitivity [5]. Hence, it might be 
beneficial for wound healing as tissue resistance to 
insulin has been found to interfere with the healing 
of excisional skin wounds by delaying the contraction 
and re-epithelialization [6].
Bone marrow-derived mesenchymal stem cells 
(BM-MSCs) are self-renewing and expandable stem 
cells. BM-MSCs have several applications in regenera-
tive medicine as they have the capacity to differentiate 
into different types of cells such as adipocytes, osteo-
blasts, chondrocytes, hepatocytes, and cardiomyocytes 
[7]; however, their applications, in healing and repair 
of skin wounds are still under research.
Due to the urgent need to develop new treatment 
modalities to improve the healing of diabetic ulcera-
tive wounds, the current study was designed, as a novel 
research issue, to investigate the effect of combined 
administration of both metformin and BM-MSCs on 
the healing of an experimentally induced cutaneous 
wound injury in an animal model of streptozotocin 
(STZ)-induced diabetes. 
Materials and methods
Animals. Forty adult male albino rats, locally bred at the 
animal house of Kasr El-Aini, Cairo University, Egypt, with 
an average weight of 200–250 g were used in the present 
study. The animals were housed at an ambient temperature 
of 25 ± 1oC, exposed to natural daily light–dark cycles, and 
had free access to food and water ad libitum. All animal 
handling and procedures were followed and approved by the 
ethical committee and the guidelines of Kasr El-Aini animal 
house. All animal experimental procedures were carried out 
in accordance with the guidelines of National Institutes of 
Health for the care and use of Laboratory animals [8].
Chemicals. Streptozotocin was obtained from Sigma-Aldrich 
(St. Louis, MO, USA). Metformin tablets (Glucophage 
500 mg tablets) were purchased from Minapharm (Cairo, 
Egypt), under license of Merck Santé, Semoy, France). 
Metformin tablets were grinded and suspended in 0.5% 
carboxymethyl cellulose (CMC) according to previous work 
[9], and afterwards shaken to obtain a suspension form of 
50 mg/ml.
Rat excision wound model. The fur on the back of the 
anesthetized rats was removed via light application of de-
pilatory cream and cleaned with alcohol swab. According to 
Dunn et al., 2013 [10], two circular 10 mm (1 cm) diameter 
full-thickness excision wounds were made on the dorsum of 
each anesthetized rat (ketamine, 100 mg/kg, intraperitoneal) 
[9], using sterile punch biopsy forceps. Hemorrhage, if any, 
was controlled by pressure application of sterile gauze. The 
wound size was chosen to be about 10 mm to compensate 
for the possible decrease in the incision diameter caused by 
wound contraction [11]. After wounding, the exposed raw area 
was covered by non-adherent gauze for about 24 hours to pre-
vent tissue fluid loss. The rats were kept in an individual cage 
under specific pathogen free conditions in an animal room.
Streptozotocin-induced diabetes. Diabetes was induced by 
a single intravenous (IV) injection of sterile STZ in sodi-
um citrate (0.1 mol/L, pH 4.5) to overnight-fasted animals 
through tail vein. STZ was given immediately once prepared, 
at a dose of 60 mg/kg body weight as described in previous 
studies [12]. After 3 days, diabetic states of rats were checked 
via blood samples withdrawn from the tail veins of these rats 
to determine fasting blood glucose level using blood glucose 
tests strips and meter (Accu-Check; Roche Diagnostics, 
Penzberg, Germany). On day 21 after injection, the animals 
were fasted for 8 h and blood glucose was measured. Animals 
with fasting blood glucose level equal to or more than 250 
mg/dl were considered as established STZ-induced diabetic 
rats [12], and were included in the experiment (Table 1).
Wound closure analysis. The wound diameters were meas-
ured on postoperative days 3, 7, 14, and 21 (Table 1). Wound 
closure was assessed as a percent reduction in the wound 
area. Progressive decrease in the wound area was followed 
by tracing the wound margin on a transparent paper. After 
that, the tracing was placed on a graph paper and the number 
of squares was counted. Wound closure was expressed as 
percentage reduction of the original wound area and was 
calculated using the following formula as demonstrated in 
previous work [13]: 
% wound closure in day N = (area on day 0  
– area on day N)/area on day 0 × 100
The area on day 0 is defined by the trace obtained immedi-
ately after wounding (the original wound area).
Experimental groups. Three weeks after induction of dia-
betes, the diabetic rats had undergone excisional wounds on 
their backs as described previously [10] and were randomly 
assigned into four groups, ten rats each (Table 1).
Group I: diabetic group (positive control). Five rats received 
0.5 ml phosphate buffer saline (PBS), injected intradermally 
at eight different sites in the wound margins and five rats 
received 0.5% CMC by gastric lavage.
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Group II: metformin-treated group. Ten rats received 
metformin (250 mg/kg/d) for 21 days after wound creation, 
by gastric lavage.
Group III: mesenchymal stem cell-treated group. Ten rats re-
ceived single intradermal injections of MSCs (2×106 in 0.5 ml 
of PBS) at eight different sites in the wound margins [14].
Group IV: combined therapy group. Ten rats received both 
metformin (250 mg/kg/d by gastric lavage for 21 days) and 
single intradermal injections of MSCs (2×106) as described 
for Group III.
Isolation and culture of the bone marrow derived MSCs. 
Rat mesenchymal stem cells were isolated according to the 
protocol described by Hu et al. [15] with minor modifications. 
After anesthesia of 8 week-aged rats, the femur and tibia were 
aseptically dissected and cleared of all muscles and connective 
tissue. Bone marrow was collected by flushing each long bone 
with complete culture medium constituted of Dulbecco’s 
Modified Eagle’s medium (DMEM) 10% fetal calf serum 
(FCS), 2 mM glutamine and penicillin/streptomycin (50 U/ml 
and 50 mg/ml, all from Sigma), supplemented with heparin 
at a final concertation of 5 U/ml. Collected marrow samples 
were mechanically disrupted by passing them successively 
through 18-gauge and 20-gauge needles to obtain a single cell 
suspension. The cells were centrifuged and resuspended with 
culture medium and incubated at humidified 5% CO2 and 
95% air atmosphere at 37°C. BM-MSCs were first selected by 
their adherent property preferentially attaching to uncoated 
polystyrene tissue culture dishes [16]. The non-adherent cells 
were removed by 2–3 washes with PBS and adherent cells 
were further cultured in complete medium. For cell passag-
ing, trypsin-EDTA solution (Sigma) was used. The medium 
was changed after 2 days and twice a week thereafter. When 
large colonies of primary MSCs developed (80–90% conflu-
ence), they were trypsinized (trypsin-EDTA solution) for 
5 min at 37°C. The resulting cell suspension was centrifuged 
at 1,500 rpm for 5 min, resuspended in complete culture 
medium. Fibroblast-like cells became the predominant cells 
in culture, characterized by their fusiform shape and plas-
tic adhesiveness. The recovered cells were counted, using 
hemocytometer and cellular viability was quantified by the 
trypan blue exclusion test in which the viable cells appeared 
with clear cytoplasm (not stained) [17]. Up to 3 cell passages 
were used in this experiment.
Flow cytometry. Extended effort was afforded for immunophe-
notyping of the separated, purified MSCs using flow cytometry 
(Accuri, San Jose, CA, USA). The cell suspension was incubat-
ed with different fluorescently labeled monoclonal antibodies 
against rat CD45, CD29, and CD90 molecules [18]. The BM-
MSCs were positive for the MSCs markers (CD29 and CD90) 
and negative for the hematopoietic-lineage marker, CD45.
Histological procedure. On day 21 after wound creation, the 
rats were euthanized with an overdose of ether. Skin tissue 
samples were collected including the wounded tissues and 
the surrounding normal skin. The tissues were immediately 
fixed in 10% neutral-buffered formalin and processed for 
paraffin sections. Five micrometer-thick sections were cut 
and stained with hematoxylin and eosin (H&E) for morpho-
logical observations, and Masson’s trichrome staining for the 
evaluation of collagen disposition, as based on previously 
stated protocols [19]. Immunohistochemical (IHC) reaction 
was done, according to previously mentioned protocols [20], 
for the detection of expression of CD31 (PECAM-1) by 
a specific antibody, mouse monoclonal antibody (Labvi-
Table 1. Illustration of the workflow of the current study
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• End of the experiment
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sion corporation, Fremont, CA, USA). It was supplied as 
a prediluted antibody ready for staining formalin-fixed and 
paraffin-embedded tissues. The sections were incubated with 
the primary antibody diluted to a concentration of 1:100 
in PBS for one hour, followed by a reaction with biotinylated 
secondary antibody. After conjugation with streptavidin–bi-
otin–peroxidase complex, 3,3-diaminobenzidine (DAB) was 
used as a chromogen, and hematoxylin solution was used 
as a counterstain. The reaction gives brownish discolora-
tion in the plasma membrane of capillary endothelial cells 
in addition to macrophages and fibroblasts [21]. Initially, 
immunofluorescence detection of PKH26-labeled MSCs 
was done by fluorescent microscope in unstained paraffin 
sections for tracking of stem cells.
Morphometric measurements. Quantitative morphometric 
measurements of the mean area percent of CD31 immu-
nostained skin sections were done using the image analyzer 
computer system (Leica Qwin 500, Leica, Cambridge, Eng-
land). The image analyzer was first calibrated automatically 
to convert the measurement units (pixels) produced by the 
image analyzer program into actual micrometer units. For 
each group, ten measuring fields in each specimen were ran-
domly selected, using the high power magnification (×400).
Statistical analysis. All the data obtained were presented 
as mean ± standard deviation (SD). The normal distribu-
tion of the values in the different groups of the study was 
checked and the evaluation of differences between groups 
was performed using one-way analysis of variance (ANO-
VA) and post hoc LSD test with SPSS 19.0 software (IBM 
SPSS Statistics for Windows, Armonk, NY, USA). Results 
with P-value of less than 0.05 were considered statistically 
significant.
Results
Characterization of bone marrow-derived  
MSCs in culture
Using inverted microscope, MSCs were identified 
in culture as spindle-shaped cells between rounded 
cells (Fig. 1). On day 2 of primary culture of MSCs 
presented as rounded nonadherent refractile cells 
(black arrows) (Fig. 1A, B) and few spindle-shaped 
cells (white arrows) (Fig. 1B). On day 3 (Fig. 1C) of 
primary culture many spindle cells (white arrows) 
were visible between rounded nonadherent refractile 
cells (black arrows). On day 7 (Fig. 1D), numerous 
spindle-shaped MSCs (white arrows) were seen. 
Evaluation of wound healing
Wound areas of each diabetic rat in the studied groups 
were measured on day 3, 7, 14 and 21 post wounding 
(Table 2 and Fig. 2). The area percentage of wound 
Figure 1. Inverted microscope photomicrographs of primary cultures of bone-marrow-derived mesenchymal stem cells 
(MSCs) on days 2 (A and B), 3 (C), and 7 (D). Panel (A) shows rounded nonadherent refractile cells (black arrows). Panel 
(B) shows few spindle-shaped cells (white arrow) between rounded nonadherent refractile cells (black arrow). Panel (C) 
shows many spindle cells (white arrow) between rounded nonadherent refractile cells (black arrow). Panel (D) shows many 
purer spindle shaped cells (white arrow).
A B
C D
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closure increased significantly in the combined ther-
apy group (MSCs plus metformin) compared to the 
metformin (p < 0.05) and MSCs (p < 0.05) groups at 
3, 7, 14 days after wounding. On day 21 after surgery, 
94% wound closure was reached in the combined 
therapy group, while non-treated, metformin-treated 
and stem cell-treated wounds reached 69.4%, 74%, 
and 75% closure, respectively. 
Morphological study of MSCs and wound sections
Using fluorescent microscopy, examination of un-
stained paraffin sections was carried out to track 
PKH26-labeled bone marrow-derived MSCs. The 
PKH26-labeled stem cells emitted red fluorescence 
(Fig. 3).
Histological examination of H&E-stained skin 
sections from control diabetic rats (Group I) showed 
skin defect covered by poorly regenerated interrupted 
epidermis. The underlying papillary dermis looked 
loose and irregular (Fig. 4A). In both Group II and 
III (metformin- and MSC-treated groups, respec-
tively), signs of partial healing were observed, such 
as formation of large amount of dermal granulation 
tissue filling the wound defect area, thin regenerat-
ed epidermis creeping over the granulation tissue, 
formation of new blood capillaries (Figs. 4B and 
Table 2. Changes in the wound areas of the studied groups of diabetic rats at different days post-wounding
Groups of rats Wound surface area (cm2) in post excision days
3rd day 7th day 14th day 21st day
Control 
(Gr. I)
0.905 ± 0.01  
(9.5%)
0.852 ± 0.12  
(14.8%)
0.550 ± 0.01  
(45%)
0.305 ± 0.11  
(69.5%)
Metformin-treated  
(Gr. II)
0.848 ± 0.14c  
(15.2%)
0.705 ± 0.15c  
(29.5%)
0.405 ± 0.01c  
(59.5%)
0.260 ± 0.10c  
(74%)
MSC-treated
(Gr. III)
0.846 ± 0.11b  
(15.4%)
0.75 ± 0.01b  
(24.7%)
0.347 ± 0.02b  
(65.4%)
0.251 ± 0.2b  
(74.9%)
Metformin- and MSC-treated 
(Gr. IV)
0.501 ± 0.19a  
(49.9%)
0.402 ± 0.01a  
(59.8%)
0.203 ± 0.01a  
(79.7%)
0.061 ± 0.11a  
(93.9%)
Diabetes was induced by streptozotocin injection of rats as described in Methods. Data express wound area in cm2 as mean ± SD, n = 10 in each 
group. The approximate percentages of wound closure are demonstrated in brackets. aSignificantly different (P < 0.05) when compared with met-
formin- (Group II) or MSC-treated rats (Group III); bP < 0.05 when compared with non-treated wounded diabetic rats (Group I); cP < 0.05 when 
compared with non-treated groups (control). MSCs, bone-marrow-derived mesenchymal stem cells. 
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Figure 2. Rough estimation of the wound closure progress expressed as the percentages of reduction in the wound area at 
different time intervals (days 0, 3, 7, 14, and 21) in diabetic rats (control, metformin-, stem cells- or metformin and stem 
cell-treated). *Significant difference (P < 0.05) when compared at the same time-intervals with metformin- and mesenchymal 
stem cell-treated groups (Groups II and III, respectively). n =10 in each group.
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4C, respectively). In Group IV (combined therapy 
group), proper healing was observed in the form of the 
contraction of the wound area, complete re-epitheli-
zation of the wound surface, accumulation of huge 
amount of granulation tissue under the re-epithelized 
wound surface, differentiation of the epidermal cells, 
re-organization (remodeling) of the collagen fibers 
within the granulation tissue, and formation of new 
more functioning (containing red blood cells) blood 
capillaries with good regeneration of skin appendages 
(Figs. 4D, E).
Trichrome stained sections showed marked 
prominent deposition of collagen fivers in Group 
IV (stem cells plus metformin-treated animals). The 
collagen fibers appeared deeply stained, coarse and 
arranged in a network like different directions (Fig. 
5D). However, in Group I (positive control), collagen 
fibers were lightly stained and scarce (Fig. 5A), and 
increased gradually in metformin- (Group II) (Fig. 
5B) and stem cell-treated (Group III) rats (Fig. 5C).
Figure 3. Fluorescence microscopy photomicrograph of 
a section in the skin wound area of a diabetic rat from Group 
III (MSC-treated) demonstrating presence of several red flu-
orescent PKH26-labeled bone marrow-derived mesenchymal 
stem cells (white arrows). Magnification: × 400.
Figure 4. Photomicrographs of hematoxylin and eosin-stained skin sections of diabetic rats from different experimental groups. 
(A). Rat from the control group presents the wound defect area (double headed arrow) with thin poor healing epidermis 
(arrowhead) and less cell-dense connective tissue underlying dermal granulation tissue (star). (B). Skin of metformin-treated 
rat (Group II) discloses more cellular granulation tissue (star) and congested blood vessels (thick arrows). Regenerating 
thin epidermis (arrowhead) is seen overlying the granulation tissue. (C) Mesenchymal stem cell-treated rat (Group III) 
shows the dermal granulation tissue (star). Thin regenerated migratory epidermis (arrowhead) is seen extending to cover 
the granulation tissue. Small sized blood vessels are seen. (D) and (E). Rat treated with metformin and MSCs (Group IV) 
shows almost complete re-epithelization of the wound surface (arrowhead), dermal granulation tissue formation (star). Clear 
differentiation of the epidermal cells and re-organization of the granulation tissue are seen in some sections. Congested 
blood vessels and formation of new small-sized blood capillaries (thick arrows) are evident. Skin appendages (sebaceous 
gland (S) and hair follicles (thin arrows)) are well formed. Magnification: A–D ×100, and E ×400.
BA C
ED
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Immunohistochemical detection of CD31  
localization during skin wound healing 
Immunohistochemical staining of skin sections of 
diabetic rats of Group I (control) revealed moderate-
ly-intense expression of CD31 and was limited to the 
endothelial cells of blood vessels (Fig. 6A). However, 
in Groups II and III (metformin- and mesenchymal 
stem cell-treated animals, respectively), diffuse CD31 
immunoexpression was noticed in the cells of the 
reticular layer of dermis such as fibroblasts and mac-
rophages (Fig. 6B, C). In Group IV (metformin- and 
stem cell-treated rats), the CD31 immunoreaction 
was diffuse and marked with the existence of large 
number of CD31 positive cells in dermal connective 
tissue (Fig. 6D).
Histomorphological evaluation of the area percent 
of CD31 immunostaining
The data, demonstrated in Figure 7, revealed signif-
icant increase (P < 0.05) in the mean area percent 
of the CD31 immunostaining in combined therapy 
group (Group IV) when compared to either Group II 
(metformin-treated) or Group III (mesenchymal stem 
cell-treated). Compared to Group I (control), the 
CD31 area was significant higher for Groups II–IV 
(P < 0.05), while no difference was observed between 
Group II and III. 
Discussion
Diabetic foot ulcer with impaired wound healing is 
a common complication of uncontrolled diabetes 
mellitus. Untreated neglected foot ulcers could be 
complicated by gangrene and amputation with its 
bad psychological impact on these patients [22, 23]. 
Introduction of new treatment modalities is mandato-
ry to improve health status of diabetic patients. Bone 
marrow-derived stem cells are a promising stem cell 
source for regenerative medicine and wound repair. 
They can differentiate into other cell types within the 
Figure 5. Masson’s trichrome stained skin sections of the different groups of diabetic rats. (A). Rat from Group I (control) 
shows lightly stained collagen bundles. (B). Rat from Group II (metformin-treated) shows disarranged collagen bundles par-
tially filling the wound defect area. (C). Rat from Group III (mesenchymal stem cell-treated) shows the dermal granulation 
tissue with rich collagen bundles which is disorganized under the wound area. (D). Rat from Group IV (combined therapy 
group) shows marked deposition of darkly stained, heavily distributed, coarse collagen fibers. Magnification: A–D ×100.
A B
C D
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injured tissue to promote repair and regeneration of 
the skin [7, 24]. Metformin is a well-known, commonly 
prescribed oral hypoglycemic drug [4], and was found 
in healthy animals to have a wound healing effect 
against cutaneous skin injuries [25]. For this reason, 
the current study was designed to investigate the effect 
of metformin and stem cells treatment on skin wound 
healing in diabetic rats. 
Figure 7. The mean values ± SD of the area percent of CD31 immunoreactivity in the different groups of diabetic rats, the 
control group, metformin-treated, mesenchymal stem-cell-treated groups, and both metformin- and MSCs-treated-group. 
n =10. *Significant difference (P < 0.05) when compared to metformin- and bone marrow-derived stem cell-treated groups. 
#significant difference (P < 0.05) when compared to the control group.
Figure 6. CD31-immunostained skin sections of diabetic rats from the studied experimental groups. (A). Rat from Group I 
(control) reveals scarce CD31 immunoreactivity limited to the endothelial cells of blood vessels (V). (B). Rat from Group 
II (metformin-treated) shows moderate CD31 immunostaining of the endothelial cells as well as dermal connective tissue 
cells, macrophages (arrows) and fibroblasts (arrowheads). (C). Rat form Group III (mesenchymal stem cell-treated) shows 
moderate CD31 immunostaining of the endothelial cells, fibroblasts (arrowheads) and macrophages (arrows). (D). Rat from 
Group IV (combined therapy group) shows marked CD31 positive immunoreaction including endothelial cells of blood 
capillaries (V) and dermal connective tissue cells. Magnification: A–D ×400.
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Skin has a remarkable accelerated capacity for 
spontaneous wound healing. Sex hormones, in 
particular estrogens, play an important role in the 
regulation of biological processes involved in tissue 
regeneration and wound healing [26, 27]. In the 
current study, the male gender of the experimental 
animals was preferred to minimize the accelerating 
effect of endogenous estrogens on wound healing 
[26]. Experimental diabetes was induced to evaluate 
the therapeutic effects of new agents in rats in which 
the cutaneous wound healing was impaired by the 
underlying disease [28]. In order to mimic the clinical 
manifestations of human DM, streptozotocin was cho-
sen to induce diabetes in the experimental animals as 
it selectively destroys the beta cells of the pancreatic 
islets [12]. Each rat was later exposed to experimental 
creation of a full thickness excisional wound using 
a sterile punch biopsy. Given that wound healing was 
accelerated in partial thickness skin injury, the full 
thickness excision was preferred as an experimental 
skin wound model, rather than partial thickness skin 
injury to abolish the effect of endogenous stem cells 
located within hair follicles and sebaceous glands [29]. 
In the present work, there were no great gross or 
histological differences between the wounded skin of 
rats injected with PBS or those which received orally 
streptozotocin solvent (CMC) in the diabetic control 
group, so that these groups were considered the same.
Regarding the gross evaluation of wound healing 
and closure of the wound defect area at different time 
intervals throughout the experiment (days 3, 7, 14, 
and 21), it was found that approximately complete 
reduction in the wound defect area was reached in 
combined therapy group (Group IV) on day 21. There 
were no significant differences between metformin 
treatment (Group II) and BM-MSCs transplantation 
(Group III) in wound closure area. However, the 
combination of metformin and BM-MSCs showed 
significantly better curative effect over the single 
treatment modality. The current result indicated 
that stem cells, combined with metformin improved 
wound healing which was in accordance with findings 
of Seo et al. [30] who reported better effects on wound 
healing when they utilized stem cells, in combination 
with an another antidiabetic agent, exendin-4.
Histological analysis of the H&E stained skin 
sections obtained from the diabetic non-treated rats 
(Group I) revealed poor wound healing, delayed 
closure of the wound area. Poorly regenerated inter-
rupted epidermis was also noted covering the wound 
floor. The papillary layer of the dermis showed less 
dense, deficient underlying dermal granulation tissue, 
which was evidenced by the lightly stained scarce 
collagen fibers visualized by trichrome staining. Fur-
thermore, it was correlated with gross wound gapping 
and poor healing in the same group. Similar to the 
current findings, other investigators [31] revealed 
delayed cutaneous wound healing in non-treated 
diabetic rats. These findings could be supported by 
the explanation of Serra et al. who demonstrated the 
effect of diabetes on the different phases of wound 
healing: the inflammatory phase (with compromised 
immune system reactivity), the proliferative phase 
(suppressed collagen deposition and formation of 
new blood vessels) and the remodeling phase in which 
re-organization of collagen occurs to restore the tissue 
structural integrity [32].
In the treated diabetic groups of rats we noted 
that both metformin and stem cells improved heal-
ing process in experimentally induced skin wounds. 
In metformin-treated and stem cell-treated (Group 
II and Group III, respectively), histological exami-
nation revealed similar findings in the form of the 
accumulation of granulation tissue partially filling 
the wound defect area with thin regenerated creep-
ing epidermis and formation of new blood vessels. 
Masson’s trichrome stain showed more abundant 
collagen bundles than in injured control diabetic rats. 
However, the combination of both stem cells plus 
metformin (in Group IV) showed nearly complete 
re-epithelialization of the wound surface in compar-
ison to either agent alone, formation of more cellular 
granulation tissue and formation of numerous blood 
capillaries. As well, darkly stained coarse abundant 
collagen fibers were evident in Masson’s trichrome 
stained skin sections. Collagen is an important extra-
cellular matrix component that provides integrity and 
structure of skin and other tissues [33]. This notion 
supported the finding of granulation tissue forma-
tion and collagen deposition in H&E and trichrome 
stainings, respectively. The finding of combined 
therapy group suggested better curative effect not 
only through increasing rate of wound healing, but 
also ensured normalization of the wound through 
effective re-epithelialization. These findings were 
in agreement with the results of Elsharawy et al., 
(2011) [34], who reported better epidermal healing 
and accelerated revascularization of the wound when 
they utilized umbilical cord blood-derived CD34+ 
stem cells injected into the wound bed. Thus, MSCs 
from various sources can accelerate healing of skin 
wounds in diabetic rats, which offers a new possibility 
of diabetic ulcers treatment in humans.
To our best knowledge the application of bone mar-
row-derived stem cells, in combination with metformin, 
in the current study, is the first such attempt aimed at 
the improvement of the health status of diabetic patients 
through aiding diabetic wound repair and regeneration.
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Different mechanisms were postulated to explain 
the action by which BM-MSCs transplantation leads 
to tissue repair. One of these mechanisms was the dif-
ferentiation of the stem cells into mature endothelial 
cells leading to angiogenesis, or the paracrine stimula-
tion of neovascularization through the release of an-
giogenic growth factors and chemical mediators [35]. 
Differentiation into healing tissue components is also 
an important mechanism. BM-MSCs can differenti-
ate into fibroblasts and myofibroblasts so that better 
healing and contraction of the wound defect area can 
be achieved. Moreover, there was evidence suggest-
ing that BM-MSCs could recruit more fibroblasts 
and stimulate their migration from the surrounding 
tissues via chemotaxis [36, 37]. Immunohistochemical 
staining of CD31, in the present work, seems to con-
firm these mechanisms. In stem cell-treated animals 
(Group III), significant difference was found when 
compared to control group (Group I). Furthermore, 
the CD31 immunoexpression was more intense in the 
combined therapy group when compared to metform-
in- or stem cell-treated groups, where the positive 
reaction was observed in the endothelial cells of the 
blood capillaries and large number of fibroblasts and 
macrophages. This observation could support the 
angiogenic mechanisms and differentiating potential 
of the applied BM-SCs.
In metformin-treated diabetic rats, significant 
difference was found when compared to the control 
group. The wound healing effect of metformin may 
be related to the formation of new blood capillaries as 
confirmed by H&E and CD31 immunohistochemistry. 
This explanation was confirmed by other researchers 
[9] who suggested that metformin promoted angi-
ogenesis via improving the angiogenic functions of 
endothelial progenitor cells (EPCs) in diabetic mice. 
In addition, other authors [38] clarified that the 
EPCs decreased in number and functions in diabetic 
patients with subsequent vascular complications and 
impaired wound healing. Moreover, another mech-
anism was postulated to explain the wound healing 
effect of metformin. The insulin tissue resistance 
had been found to interfere with the healing of ex-
cisional skin wounds by delaying wound contraction 
and surface re-epithelialization, as shown by other 
investigators [6]. Metformin is a true insulin sensitizer 
affecting insulin action in peripheral tissues [5], which 
contributed to the indirect effect of metformin on 
wound healing.
Interestingly, in an another animal model opposite 
results were reported [39]. The authors reported re-
duction in the proliferation of HaCaT keratinocytes 
in culture media in presence of metformin. This was 
due to an alteration of the cell cycle without induction 
of apoptosis, as proven by means of flow cytometry. 
Furthermore, in a physiological setting, the authors 
revealed reduced healing process and wound closure 
progress in metformin-treated ulcers in diabetic pa-
tients. They explained their findings by suggestion that 
metformin interfered with surface re-epithelization 
of the wound area by reducing cell proliferation of 
keratinocytes [39]. The discrepancy between our and 
their results could be attributed to the different ex-
perimental design, methods and dosage of metformin. 
The angiogenic response is essential for wound 
healing. Formation of new blood vessels is necessary 
to sustain the newly formed granulation tissue and 
the survival of keratinocytes [40]. In agreement with 
this notion, the congested blood vessels scattered 
among the granulation tissue, in the current study, 
particularly in the combined therapy group confirmed 
the importance of neovascularization in maintaining 
the vitality of the newly formed granulation tissue.
Finally, the different mechanisms of wound heal-
ing encountered in each group of the single treatment 
modality can be summarized to synergistically pro-
mote better wound healing in the group of combined 
treatment modality.
In summary, the results of the current study indi-
cated a synergistic effect of both combined BM-MSCs 
and metformin on skin healing in this animal wound 
model of STZ-induced diabetes. This combination ac-
celerated wound healing and increased wound closure 
progress by stimulation of surface re-epithelization, 
differentiation, and promoting angiogenesis. The 
combined approach could be considered as a novel 
treatment modality for the management of patients 
with diabetic foot ulcers to enhance wound healing 
and to decrease the risk of progression of gangrene.
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